Advertisement

Topics

Mesoblast Company Profile

09:43 EDT 20th June 2018 | BioPortfolio

Mesoblast Limited (ASX:MSB; USOTC:MBLTY) is committed to the development of novel treatments for orthopaedic conditions, including the rapid commercialisation of a unique adult stem cell technology aimed at the regeneration and repair of bone and cartilage. Our focus is to progress through clinical trials and international regulatory processes necessary to commercialise the technology in as short a timeframe as possible. Mesoblast has the worldwide exclusive rights for a series of patents and technologies developed over more than 10 years relating to the identification, extraction and culture of adult Mesenchymal Precursor Cells (MPCs). The Company has acquired 38.4% of Angioblast Systems Inc., an American company developing the platform MPC technology for the treatment of cardiac, vascular and eye diseases including repair and regeneration of blood vessels and heart muscle. Mesoblast and Angioblast are jointly funding and progressing the core technology. Mesoblast's strategy is to maximise shareholder value through both corporate partnerships and the rapid and successful completion of clinical milestones.


News Articles [38 Associated News Articles listed on BioPortfolio]

2018 MPC-150-IM (rexlemestrocel-L; Mesoblast) Drug Analysis – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Drug analysis: MPC-150-IM” drug pipelines has been added to ResearchAndMarkets.com’s offering. MPC-150-IM (rexlemestrocel-L; Mesoblast) consis...

Review for Mesoblast's heart failure cell therapy to be fast-tracked by FDA

The FDA granted Regenerative Medicine Advanced Therapy designation to Mesoblast's mesenchymal precursor cell therapy for hear -More- 

Mesoblast’s Late-Stage Pipeline Could Be Game Changing: Are Investors Paying Attention?

Mesenchymal cell specialist Mesoblast came back from a near-death experience in 2016 when Teva returned a key asset. But recent...  

Mesoblast stem cell therapy meets goal of pediatric Graft vs. Host study

(Reuters) - Nearly 70 percent of children with potentially fatal acute Graft Versus Host Disease responded to treatment with an experimental stem cell therapy from Mesoblast Ltd, meeting the primary g...

Mesoblast and Cartherics form partnership to develop 'off-the-shelf' CAR-T therapies for solid cancers

Mesoblast Limited today announced that it has entered into a partnership with Cartherics Pty Ltd to develop allogeneic ‘off-the-shelf’ CAR-T cells armed with multiple targeting receptors for use i...

Mesoblast Appoints New Chief Financial Officer

MELBOURNE, Australia and NEW YORK, May 30, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced the appointment of Josh Muntner as its new Chief Financial Officer, bas...

Mesoblast 2018 Q3 - Results - Earnings Call Slides

Mesoblast Enters Into US$75 Million Non-Dilutive Credit Facility

MELBOURNE, Australia and NEW YORK, March 06, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced that it has entered into a US$75 million non-dilutive, four-year cr...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

Mesoblast Stem Cell Therapy for Patients With Single Ventricle and Borderline Left Ventricle

Patients under the age of 5, with a diagnosis of hypoplastic left heart syndrome (HLHS), unbalanced atrioventricular canal (uAVC), or borderline left heart who are undergoing staged LV rec...

Companies [2 Associated Companies listed on BioPortfolio]

Mesoblast Limited

Mesoblast Limited (ASX: MSB; USADR: MBLTY) is a world leader in commercializing biologic products for the broad field of regenerative medicine. Mesoblast has the worldwide exclusive rights for a serie...

Mesoblast

Mesoblast Limited (ASX:MSB; USOTC:MBLTY) is committed to the development of novel treatments for orthopaedic conditions, including the rapid commercialisation of a unique adult stem cell technology ai...

More Information about "Mesoblast" on BioPortfolio

We have published hundreds of Mesoblast news stories on BioPortfolio along with dozens of Mesoblast Clinical Trials and PubMed Articles about Mesoblast for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Mesoblast Companies in our database. You can also find out about relevant Mesoblast Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Osteoporosis
Osteoporosis is a disease in which the bones become extremely porous, are subject to fracture, and heal slowly, occurring especially in women following menopause and often leading to curvature of the spine from vertebral collapse. Follow and track&n...

Blood
Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells.  In vertebrates, it is composed of blo...


Corporate Database Quicklinks



Searches Linking to this Company Record